Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca and Amgen forge antibody alliance

Deal could lead to "important treatments across multiple indications in inflammatory disease"

AstraZeneca (AZ) has licensed a series of antibodies with potential in inflammatory diseases from US biotech major Amgen in a deal that includes upfront fees of $50m.

All told, AZ gains joint development and commercialisation rights to five Amgen antibodies which it says "offer the potential to deliver important treatments across multiple indications in inflammatory diseases".

The two companies will share costs and profits from the programmes, with AZ paying around two-thirds of the costs until 2014, and 50 per cent thereafter.

Heading the pack of antibodies is brodalumab (AMG 827), an anti-IL17 antibody that will shortly enter phase III testing in psoriasis and is in phase II for psoriatic arthritis and asthma.

Amgen is in a race to market in the anti-IL17 sector with Eli Lilly, which recently reported phase II data for rival antibody ixekizumab in psoriasis.

Amgen will take the lead on the brodalumab programme and has an existing licensing agreement with Japan's Kyowa Hakko Kirin for the antibody which is unaffected by the AZ deal.

If it wins through to market, Amgen will promote brodalumab in dermatology indications in the US and Canada, and in rheumatology indications in the US, Canada and Europe. Meanwhile AZ will promote the antibody in respiratory and in dermatology indications in all other territories.

Allocation of promotion rights for other territories, indications and molecules will be agreed later between the companies.

AstraZeneca takes the lead on the three other antibodies, all of which are in phase I development:

• AMG 139 neutralises IL-23 interaction with its receptor while sparing IL-12 and is currently being tested in Crohn's disease
• AMG 157 blocks the interaction of thymic stromal lymphopoietin (TSLP) with the TSLP receptor and has potential in asthma
• AMG 181 is an anti-alpha4/beta7 antibody in testing for ulcerative colitis and Crohn's disease.

Meanwhile, Amgen will lead the development of AMG 557, an antibody that binds to the B7 related protein (B7RP-1) and is being investigated in phase Ib for its utility in autoimmune diseases such as systemic lupus erythematosus.

Once again, Amgen has a prior licensing agreement with Takeda which is unaffected by the new alliance.

4th April 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics